We improve people's lives with innovative treatment solutions

AmorphOX® – a world-class powder technology for cutting-edge drug delivery

Discover AmorphOX

Press releases & news

All press releases

Orexo presents the third quarter

Orexo will announce the Interim Report for the third quarter of 2024 on October 24 at 8 am CET. The same day at 2 pm, analysts, investors, and media are invited to attend a presentation where Nikolaj Sørensen, CEO, and Fredrik Järrsten, CFO, will present the latest development and host a Q&A.

Links to join the call

Who we are

Orexo is a commercial-stage pharmaceutical company with an international footprint. We are passionate about improving people's lives by offering innovative treatment solutions. Today, we develop pharmaceuticals based on proprietary drug delivery technologies, the same vision as when it all started in Uppsala, Sweden, 30 years ago.

Discover more about us

Innovative treatments advancing health and well-being across diverse portfolio

Review solutions

Based on the AmorphOX technology we are developing new medications, e.g. OX640 - an intranasal epinephrine medication for allergic reactions

Discover pipeline

Together we are stronger. Team up with us for product development and commercialization.

For contact details

Meaningful sustainable outcomes for people, societies and our planet

Explore sustainability

Orexo is committed to the UN Global Compact corporate responsibility initiative and its principles in the areas of human rights, labor, environment and anti-corruption. Read more on www.unglobalcompact.org.